Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):782–788. doi: 10.1038/bjc.1991.174

Myeloid leukaemia following therapy for a first primary cancer.

A Nandakumar 1, S Davis 1, S Moolgavkar 1, R P Witherspoon 1, S M Schwartz 1
PMCID: PMC1972376  PMID: 2039704

Abstract

To evaluate the risk of second primary myeloid leukaemia due to radiotherapy and chemotherapy administered for a first primary cancer, we conducted a population-based case-control study consisting of 97 cases and 194 controls matched on age, date of diagnosis, and site of initial primary cancer among residents of 13 counties in western Washington State. The risk of myeloid leukaemia in patients who received cyclophosphamide as part of their chemotherapy regimen was 7.4 (95% confidence interval 1.3-43.8). This risk was not altered appreciably by the administration of radiotherapy. Compared to patients not receiving any chemotherapy, the relative risk among patients who received prednisone in combination with cyclophosphamide (odds ratio 44.4 95% confidence interval 4.0-496.2) was nearly four times that among patients receiving cyclophosphamide without this steroid (odds ratio 12.6 95% confidence interval 2.4-64.9). The relative risk of second primary myeloid leukaemia in patients who received both prednisone and drugs other than cyclophosphamide (odds ratio 64.2 95% confidence interval 2.6-1582) was 20 times that among patients receiving drugs other than cyclophosphamide and no prednisone (odds ratio 3.2 95% confidence interval 0.6-16.9). These risk estimates were higher when the analysis was restricted to acute myeloid leukaemia. There was no increased risk of second primary myeloid leukaemia associated with radiotherapy. The single unique finding is that the use of prednisone in chemotherapy regimens may enhance the leukaemogenic effect of other chemotherapy drugs.

Full text

PDF
782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beardsley G. P., Cohen H. J. Corticosteroid-induced lymphocytopenia in man: absence of splenic influence and effect of recipient serum. Am J Hematol. 1978;4(3):255–259. doi: 10.1002/ajh.2830040307. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. M. Classification of the myelodysplastic syndromes. Clin Haematol. 1986 Nov;15(4):909–923. [PubMed] [Google Scholar]
  3. Boice J. D., Jr, Blettner M., Kleinerman R. A., Stovall M., Moloney W. C., Engholm G., Austin D. F., Bosch A., Cookfair D. L., Krementz E. T. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst. 1987 Dec;79(6):1295–1311. [PubMed] [Google Scholar]
  4. Boivin J. F., Hutchison G. B., Evans F. B., Abou-Daoud K. T., Junod B. Leukemia after radiotherapy for first primary cancers of various anatomic sites. Am J Epidemiol. 1986 Jun;123(6):993–1003. doi: 10.1093/oxfordjournals.aje.a114351. [DOI] [PubMed] [Google Scholar]
  5. Boivin J. F., Hutchison G. B. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst. 1981 Oct;67(4):751–760. [PubMed] [Google Scholar]
  6. Curtis R. E., Hankey B. F., Myers M. H., Young J. L., Jr Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience. J Natl Cancer Inst. 1984 Mar;72(3):531–544. [PubMed] [Google Scholar]
  7. Einhorn N. Acute leukemia after chemotherapy (melphalan). Cancer. 1978 Feb;41(2):444–447. doi: 10.1002/1097-0142(197802)41:2<444::aid-cncr2820410210>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  8. Greene M. H., Boice J. D., Jr, Greer B. E., Blessing J. A., Dembo A. J. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982 Dec 2;307(23):1416–1421. doi: 10.1056/NEJM198212023072302. [DOI] [PubMed] [Google Scholar]
  9. Greene M. H., Harris E. L., Gershenson D. M., Malkasian G. D., Jr, Melton L. J., 3rd, Dembo A. J., Bennett J. M., Moloney W. C., Boice J. D., Jr Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986 Sep;105(3):360–367. doi: 10.7326/0003-4819-105-3-360. [DOI] [PubMed] [Google Scholar]
  10. Greene M. H., Young R. C., Merrill J. M., DeVita V. T. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res. 1983 Apr;43(4):1891–1898. [PubMed] [Google Scholar]
  11. Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Möhner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987 Feb;55(2):213–218. doi: 10.1038/bjc.1987.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jacobs A. Human preleukaemia: do we have a model? Br J Cancer. 1987 Jan;55(1):1–5. doi: 10.1038/bjc.1987.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Koeffler H. P. Myelodysplastic syndromes (preleukemia). Semin Hematol. 1986 Oct;23(4):284–299. [PubMed] [Google Scholar]
  14. Kushner B. H., Zauber A., Tan C. T. Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1988 Oct 1;62(7):1364–1370. doi: 10.1002/1097-0142(19881001)62:7<1364::aid-cncr2820620721>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  15. Penn I. Second neoplasms following radiotherapy or chemotherapy for cancer. Am J Clin Oncol. 1982 Feb;5(1):83–96. [PubMed] [Google Scholar]
  16. Portugal M. A., Falkson H. C., Stevens K., Falkson G. Acute leukemia as a complication of long-term treatment of advanced breast cancer. Cancer Treat Rep. 1979 Feb;63(2):177–181. [PubMed] [Google Scholar]
  17. Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
  18. Rosner F., Carey R. W., Zarrabi M. H. Breast cancer and acute leukemia: report of 24 cases and review of the literature. Am J Hematol. 1978;4(2):151–172. doi: 10.1002/ajh.2830040207. [DOI] [PubMed] [Google Scholar]
  19. Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]
  20. Tucker M. A., Meadows A. T., Boice J. D., Jr, Stovall M., Oberlin O., Stone B. J., Birch J., Voûte P. A., Hoover R. N., Fraumeni J. F., Jr Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 1987 Mar;78(3):459–464. [PubMed] [Google Scholar]
  21. Valagussa P., Santoro A., Fossati Bellani F., Franchi F., Banfi A., Bonadonna G. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood. 1982 Mar;59(3):488–494. [PubMed] [Google Scholar]
  22. Valagussa P., Santoro A., Fossati-Bellani F., Banfi A., Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986 Jun;4(6):830–837. doi: 10.1200/JCO.1986.4.6.830. [DOI] [PubMed] [Google Scholar]
  23. Wolf B. C., Neiman R. S. The bone marrow in myeloproliferative and dysmyelopoietic syndromes. Hematol Oncol Clin North Am. 1988 Dec;2(4):669–694. [PubMed] [Google Scholar]
  24. van der Velden J. W., van Putten W. L., Guinee V. F., Pfeiffer R., van Leeuwen F. E., van der Linden E. A., Vardomskaya I., Lane W., Durand M., Lagarde C. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer. 1988 Aug 15;42(2):252–255. doi: 10.1002/ijc.2910420218. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES